COVID-19 Update #142 10/14/2022

The FDA amended the EUAs for the Moderna and Pfizer-BioNTech COVID-19 bivalent booster vaccines to include children and adolescents. Both vaccine can be given at least two months after the last booster vaccination. The Pfizer-BioNTech COVID-19 Vaccine is approved for patients five years and older. The Moderna vaccine is approved for patients six years and older.


Pfizer and BioNTech announced early interim data from a 900 patient, Phase II/III trial (NCT05472038), which demonstrated an increase in antibody titers for the Omicron BA.4 and BA.5-subvariants seven-days after immunization with their bivalent booster vaccine